Expert analysts

Our experts have backgrounds in diverse areas that include the pharmaceutical industry, academia, pharmacology, health economics, epidemiology and statistics. We have experts at every level, from doctorate and master’s-level researchers, to seasoned clinical pharmacists.

Alasdair Godfrey

Alasdair Godfrey

Owner, Operator & Director

Alasdair Godfrey joined Health Technology Analysts (formally Optum) as Senior Director and Asia Pacific Leader in February of 2014. Alasdair is now co-owner/operator with strategic oversight of all projects including manuscripts, reimbursement submissions, feasibility studies, systematic reviews and clinical practice guidelines. Alasdair has had varied roles in the medical device and pharmaceutical industries and medical market access consulting. As a market access and health policy expert Alasdair has been an evaluator for the Australian Medical Services Advisory Committee (MSAC) managing several complex evaluations of medical devices, co-dependent technologies, diagnostic tests and clinical procedures.

Prior to HTAnalysts Alasdair had autonomous responsibility for health outcomes research at a large global pharmaceutical company. During this time Alasdair participated in a variety of consultative groups and expert committees for biosimilars and medical devices with the Pharmaceutical Benefits Division (PBD), Pharmaceutical Benefits Advisory Committee (PBAC) and the Medical Technology Association of Australia (MTAA) regarding patient access, policy and reimbursement. Alasdair has a medical and scientific background with degrees in medicine and genetics.

Before moving to Australia in early 2000’s Alasdair held clinical, research and academic positions in the UK (Cambridge and Glasgow) mainly focused in the therapeutic areas of oncology and autoimmune diseases. Alasdair has interests in genetic research, global and regional health policy and equitable access to best healthcare.

Colman Taylor PhD

Colman Taylor PhD

Owner, Operator & Director

Dr Colman Taylor joined HTAnalysts in May 2014 and is now co-owner and Director. During his employment with HTAnalysts, Colman has managed over 100 projects including multiple reimbursement submissions, economic model development and adaptions, costing studies, go-to-market and market access strategy projects, policy recommendations as well as late phase projects in Australia and the Asia Pacific. As part of HTAnalysts role as a member of the Australian Department of Health HTA Panel, Colman has managed several government sponsored evaluations of HTA submissions including protocols and submission based assessments for MSAC.

In the area of health policy, Colman facilitated the development of a multi-stage industry agreed framework for guidelines for rare disease therapies and has also presented to the Review Committee of the Life Saving Drugs Programme. Colman also led a multi-country go-to-market strategy for a new therapy, working with a cross-functional team, which culminated in value, strategy and pricing recommendations. Prior to joining HTAnalysts, Colman worked for Novartis Pharmaceuticals where he managed and contributed to several submissions to the PBAC for high profile products as well as managing late phase studies and surveys including discrete choice experiments and chart reviews. Within these submissions Colman built and adapted several economic models and represented Novartis in an ‘enhanced pre-submission process’ with the Department to resolve modelling related issues. Colman has a strong background in academia and currently holds positions with The George Institute for Global Health (Post-Doctoral Research Fellow) and The University of NSW (Conjoint Senior Lecturer) as well as being a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Australia Chapter Committee.

Colman completed his PhD studies at the George Institute – examining the cost and benefit of helicopter emergency medical services. He has been a lead author or co-author on >40 peer reviewed publications (including The Lancet and NEJM), >35 conference proceedings and has provided several invited speaker presentations. He is also an active reviewer for several international and local journals and has been granted over $15m in peer-reviewed funding through bodies such as the NHMRC.

Adèle R Weston PhD

Adèle R Weston PhD

Principal Scientist

Dr Weston was a co-founder of HTAnalysts. Dr Weston has worked in health technology assessment and health economics consultancy for the past 19 years. During this time she has prepared in excess of 200 reimbursement submissions to PBAC, NICE and other HTA agencies globally, as well as serving as a government HTA evaluator. Dr Weston has a particular interest in the integration of clinical and economic evidence in the evaluation of diagnostic, screening and targeted technologies. She is also active in the area of utility valuation and healthcare resource use quantification to demonstrate product value and defend price, with particular reference to the Asia Pacific region.

Dr Weston has considerable experience in value-based pricing, including development of risk-share arrangements and pay-for-performance schemes. Dr Weston has authored Phase 4 study protocols in several therapeutic areas. Dr. Weston has a PhD in physiology and has authored more than 30 peer-reviewed publications including in The Lancet and NEJM. She has previously held academic appointments at the University of Natal Medical School and the University of Sydney. Dr. Weston served several terms on the Australian NHMRC panel of evidence-based health advice reviewers, co-authored HTA methodology publications, and continues to provide methodological advice in the development of clinical practice guidelines to government and not-for-profit organisations.

Lachlan Standfield PhD

Lachlan Standfield PhD

Principal Economist

Dr Lachlan Standfield has worked in health economics consultancy for over fifteen years. During this time he has played a significant role in over 100 reimbursement submissions to PBAC, MSAC, CADTH, NICE, PHARMAC and other international reimbursement agencies. He has also managed an MSAC evaluation group for the Department of Health and Ageing in Australia, conducted assessments of medical technologies for the New Zealand Ministry of Health, lectured on health economics at The University of Melbourne and provided tailored health economics training for both pharmaceutical and medical device industry clients. 

Dr Standfield has completed economic analyses of a wide array of co-dependent, public health, pharmaceutical, medical device, diagnostic, health service delivery and screening interventions for government and private clients. These analyses have spanned a broad array of therapeutic areas including: Cardiovascular, Dermatology, Endocrinology, General Practice, Gastroenterology, Genetic Diseases, Haematology, Hepatology, Immunology, Infectious diseases, Musculoskeletal, Nephrology, Neurology, Nutrition and Weight Loss, Obstetrics and Gynaecological, Oncology, Ophthalmology, Orthopaedics, Paediatrics, Psychiatry, Respiratory, Rheumatology and Trauma. He also has extensive experience conducting financial impact modelling and risk-share scenario analyses.

Dr Standfield has significant clinical experience and experience in developing and adapting Decision Tree models, Markov cohort models, microsimulations, discrete event simulations, agent-based models and mixed-method simulations. He has a high level of expertise in the use of Microsoft Excel®, TreeAge®, Simul8® and AnyLogic® modelling software. Dr Standfield completed his doctoral studies with the Centre for Applied Health Economics, Menzies Health Institute Queensland, Griffith University, focusing on the application of economic modelling methods used to model capacity constraints as they pertain to orthopaedics, aged care, Alzheimer’s disease and other dementias.

Margaret Jorgensen PhD

Margaret Jorgensen PhD

Associate Director BMedSc (Hons l), PhD Molecular Microbiology

Dr. Jorgensen joined HTAnalysts in March 2013 and has over 20 years of experience in the medical research, pharmaceutical and consulting industries. While with HTAnalysts, Margaret has led the development of 2 clinical practice guidelines, conducted numerous rigorous systematic reviews and contributed to several PBAC and MSAC reimbursement submissions. Dr. Jorgensen has also participated in the preparation of manuscripts and the adaptation of global health economics models for a variety of industry and non-industry clients. During her career, Dr Jorgensen has gained diverse therapeutic knowledge across a range of disease areas including infectious diseases, oncology, mental health, natural therapies and patient blood management.

Prior to joining HTAnalysts, Dr. Jorgensen worked for the Health Policy Division of The George Institute for Global Health where she provided key stakeholders such as the Bill & Melinda Gates Foundation, the World Bank, and the International AIDS Vaccine Initiative with evidence-based research to support policy decisions for neglected diseases. This included the development of a Global Survey for Funding of Innovation for Neglected Diseases and an in-depth analysis of future funding demands for malaria drug and vaccine development. Margaret gained her extensive experience in critical appraisal, data analysis, treatment surveys, decision trees, and report writing whilst employed as a research analyst at Decision Resources, Inc. Here, she provided biopharmaceutical companies with and in-depth research and competitive intelligence as to the trends, emerging developments, and market potential of drugs & vaccines within the major pharmaceutical markets (US, Japan, UK, Germany, France, Italy, and Spain). Dr. Jorgensen also has prior experience managing late-phase clinical trials across several geographic regions. Margaret obtained her Bachelor of Medical Science (Hons) degree from the University of Sydney and completed her Ph.D. at the University of New South Wales. She received postdoctoral training at the Harvard University School of Public Health and has published a number of articles in peer-reviewed journals.

Francis Dehle PhD

Francis Dehle PhD

Associate Director BBioMedSc, PhD Pharmacology

Dr Francis Dehle joined HTAnalysts in July 2011 and is now an Associate Director. While with HTAnalysts, Francis has contributed to reimbursement submissions to PBAC and MSAC, observational study design reporting, global health economic model adaptations, feasibility briefs and preparation of manuscripts. Between 2015 and 2018, Francis worked for Boehringer Ingelheim where he managed and contributed to submissions to the PBAC in the areas of diabetes and respiratory diseases. Francis re-joined HTAnalysts in October 2018. During his career, Francis has conducted numerous systematic reviews including of RCTs, observational studies, and economic literature in the therapeutic areas of Alzheimer’s disease, asthma, COPD, diabetes, osteoporosis, oncology and osteoarthritis.

 

Prior to joining HTAnalysts, Francis worked as a post-doctoral researcher at the Department of Thoracic Medicine, Royal Adelaide Hospital and the School of Chemistry & Physics, The University of Adelaide. Francis completed a PhD in Pharmacology at The University of Adelaide and has published a number of articles on macrophage function in COPD and lung cancer, and the protein dynamics of amyloid formation in peer-reviewed journals.

Rita Karamy

Rita Karamy

Engagement Manager BPharm, GDip (Health Economics & Policy)

Rita Karamy joined HTAnalysts in July 2014 as a Health Economics and Outcomes Research Consultant. Prior to starting with HTAnalysts, Rita worked in various medical affairs related roles at a pharmaceutical company. During her time with HTAnalysts, Rita has contributed to several MSAC and PBAC submissions. Within these submissions, Rita has undertaken review of clinical data and treatment algorithms, and has been involved in preparation of cost effectiveness and budget impact models. Rita has also been involved in submission strategy and development of frameworks and surveys to accompany submissions. 

Of particular interest, Rita developed an implementation framework for a novel implantable pulmonary artery pressor device in patients with heart failure, worked on an MSAC submission for a point of care testing device within the primary healthcare setting, and was secretariat of the rare diseases working group. Outside of work with HTAnalysts, Rita is a registered pharmacist.

Irene Deltetto

Irene Deltetto

Engagement Manager BSc, Msc, MPH

Irene Deltetto joined HTAnalysts in January 2015 as a Senior Consultant before being promoted to Engagement Manager in March 2017. Irene holds a Bachelor of Science in International Management and a Master of Science in Economics and Management, both from the Universita` Bocconi (Milan, Italy) and a Master in Public Health from the University of Sydney (Sydney, Australia). Prior to working at HTAnalysts, Irene worked in management consulting at EY Italy, as part of their market access team, where she contributed to EMA submissions, including the development of economic models and the drafting of core value dossiers.

In addition, she built business models for pharmaceutical companies, as well as designed dialysis and cancer care networks for public health authorities. During her time with HTAnalysts, Irene has contributed to several PBAC and PHARMAC submissions. Within these submissions, Irene has undertaken literature searches and critical appraisal of the literature, built economic and financial models, and contributed to submission strategy. Irene built and adapted several economic models, including both cost-effectiveness and budget impact models. Irene was also involved in multiple strategic market access projects, including a multi-country go-to-market strategy for a new therapy which culminated in value, strategy and pricing recommendations.

Santwona Baidya PhD

Santwona Baidya PhD

Senior Consultant BSc (Hons l), PhD, PGCert (Public Health)

Santwona Baidya joined HTAnalysts in December 2011 as a Research Analyst. Since joining, Santwona has been promoted to Senior Consultant. Santwona holds a Bachelor of Science with 1st Class Honours, a PhD in Obstetrics and Gynaecology and a Postgraduate Certificate in Public Health, with the studies completed at the University of Auckland in New Zealand. During her time at HTAnalysts, she has contributed to and managed several PBAC submissions, including co-dependant submissions.

Within these submissions, she has worked on systematic reviews, budget impact models, development of treatment algorithms and been involved in devising submission strategy. Santwona has contributed to clinical guidelines and feasibility studies. She has also worked on several multi-country, late phase clinical studies, with contributions made to study design and protocol development, statistical analysis and interpretation of data, report writing, and numerous conference abstracts and scientific manuscripts. Santwona has worked on projects focused in multiple therapeutic areas including oncology, neurological disorders, osteoporosis, respiratory conditions and developmental disorders.

Andrea Cowley PhD

Andrea Cowley PhD

Senior Consultant BMedSc (Hons l), PhD (Medicine, Neuroscience)

Andrea Cowley joined HTAnalysts in December 2016 as a consultant. Prior to joining HTAnalysts, Andrea worked as a Medical Writer at Clinical Research Corporation and NPS MedicineWise. Her duties included systematic literature review, critical appraisal, and developing and writing market analysis reports, educational content and state of the art presentations. While at NPS MedicineWise Andrea was also involved in projects with the Australian Government Department of Health, particularly the Medical Services Advisory Committee and Medicare Benefits Schedule Reviews Unit. In these projects, her responsibilities included providing secretariat support, liaising with KOLs, and writing meeting minutes and consultation papers. Andrea has completed Program 1 of the Medicines Australia Continuing Education Program.

In 2008 Andrea was awarded a PhD from the University of New South Wales and continued on as a post-doctoral researcher at the Garvan Institute till 2014. Her research focused on stem cell biology, regeneration and immunology in neurological disorders. During this time Andrea published in peer-review journals such as Proceedings of the National Academy of Science, Journal of Neuroscience and Stem Cells, and was a regular reviewer for Journal of Neurochemistry. Andrea also holds a Bachelor of Medical Science (Hons I) from the University Of Sydney and is currently undertaking a Master of Public Health (Health Economics) at the University of New South Wales.

During her time with HTAnalysts, Andrea has contributed to several feasibility studies; PBAC, MSAC and co-dependent and PHARMAC submissions; and has been involved in several advisory boards. Within these projects, Andrea has undertaken systematic literature reviews, critical appraisal, data analysis and has contributed to submission strategy. Andrea has a diverse knowledge of multiple therapeutic areas including cardiovascular, endocrinology, gastroenterology, genomics,  immunology, infectious disease, neurology, neuroscience, oncology, ophthalmology, pain and vaccines.

Stephanie Allerdice

Stephanie Allerdice

Consultant BSc (Hons)

Stephanie Allerdice joined HTAnalysts in May 2016 as a consultant. Prior to working at HTAnalysts, Stephanie was studing a Doctor of Philosophy at the Garvan Insistute of Medical Research and the Kinghorn Cancer Centre, in breast cancer research, with a focus on tamoxifen resistance. Stephanie holds a Bachelor of Science (Hons I) from the University of Sydney, Australia, where she majored in neuroscience and completed her honours investigating the role of astrocytes in the pathology of Parkinson’s disease.

During her time with HTAnalysts, Stephanie has contributed to several MSAC applications and PBAC applications. Within these submissions, Stephanie has conducted systematic reviews, indirect comparisons and has contributed to submission strategy. Stephanie also has experience with medical devices, including submissions to the Prostheses List and applications to the US Food and Drug Administration (FDA). Stephanie has previously worked in many therapeutic areas including, oncology, autoimmune diseases, immunotherapy and diagnostic tools. Stephanie has built epidemoligcal models to provide accurate estimates of relevant patient populations.

Adrian Peacock

Adrian Peacock

Consultant BAppSc, MHTI

Adrian joined HTAnalysts in May 2018 as a Consultant. Prior to joining HTAnalysts, Adrian completed his Master of Health Technology Innovation at The University of Sydney. After completing his Bachelor of Applied Science (Chiropractic) at Macquarie University, Adrian identified health information technology and medical innovation as areas where he could pursue his passions for research and health. During his Masters degree, Adrian undertook various medical device health technology assessment projects within the University’s Charles Perkins Centre, including robotic surgery, tissue engineering and regenerative medicine.

Additionally, he developed an agent-based model of chronic disease management, and analysed the data produced to determine the most effective mode of delivering social based health interventions to improve population health. The relating journal article he composed was shortlisted for the Branco Cesnik Award and published at the HISA 2017 Health Informatics Conference, and Adrian was awarded a place on the University of Sydney’s School of IT Postgraduate Honour Roll for his work.

Kevin Phan

Kevin Phan

Consultant BBioMedSc

Kevin Phan joined HTAnalysts in October 2018 as a Consultant. Kevin holds a Bachelor of Biomedical Science from Monash University and is currently studying a Master of Public Health in Health Economics also at Monash University.

Prior to working at HTAnalysts, Kevin worked as an intern at AbbVie, as part their market access team, where he made substantial contributions and led sections for PBAC and PHARMAC submissions, including development of budget impact models. In addition, he has conducted commercial assessment and feasibility updates as part of the gastroenterology brand team. He was also heavily involved in pricing, biosimilar impact and submission strategy whilst working across the immunology, oncology and specialty care portfolios.

Lynn Rainey

Lynn Rainey

Business Operations Manager

Lynn joined HTAnalysts in 2006 and is the Business Operations Manager. Lynn brings over 30 years of administrative & finance experience in office management,book keeping, procurement and logistics across various industries including the Australian Stock Market, imaging technology, legal costing, construction and small business.

As a multi-software platform expert Lynn also manages the quality control, security and formatting design of our projects. Lynn ensures all our documentation is presented to the highest standards, meets guideline criteria and keeps our clients confidential information secure.